Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2023

07-04-2023 | Visceral Ischemia | Original Article

Thromboembolic Events in Hospitalized Patients with Inflammatory Bowel Disease

Authors: Alfred D. Nelson, Daniela Fluxá, Freddy Caldera, Francis A. Farraye, Jana G. Hashash, Paul T. Kröner

Published in: Digestive Diseases and Sciences | Issue 6/2023

Login to get access

Abstract

Background

Inflammatory bowel disease (IBD) has been associated with an increased risk of thromboembolic vascular complications. Although studies from the National Inpatient Sample (NIS) examined this association to some extent, sub-stratification for Crohn’s disease (CD) and ulcerative colitis (UC) in larger studies is lacking. The aims of this study were to utilize the NIS to determine the prevalence of thromboembolic events in inpatients with IBD compared to in patients without IBD and to explore the inpatient outcomes like morbidity, mortality, and resource utilization in patients with IBD and thromboembolic events as stratified by disease subtype.

Methods

This was a retrospective observational study using the NIS 2016. All patients with ICD10-CM codes for IBD were included. Patients with thromboembolic events were identified using diagnostic ICD codes and stratified into 4 categories: (1) Deep vein thrombosis (DVT), (2) Pulmonary embolism (PE), (3) Portal vein thrombosis (PVT), and (4) Mesenteric ischemia, which were then sub-stratified for CD and UC. The primary outcome was the inpatient prevalence and odds of thromboembolic events in patients with IBD compared to without IBD. Secondary outcomes were inpatient morbidity, mortality, resource utilization, colectomy rates, hospital length of stay (LOS), and total hospital costs and charges compared to patients with IBD and thromboembolic events.

Results

A total of 331,950 patients with IBD were identified, of who 12,719 (3.8%) had an associated thromboembolic event. For the primary outcome, after adjusting for confounders, inpatients with IBD had higher adjusted odds of DVT (aOR 1.59, p < 0.001), PE (aOR 1.20, p < 0.001), PVT (aOR 3.18, p < 0.001) and mesenteric ischemia (aOR 2.49, p < 0.001) compared to inpatients without IBD, an observation which was confirmed for both patients with CD and UC. Inpatients with IBD and associated DVT, PE and mesenteric ischemia had higher morbidity, mortality, odds of colectomy, cost, and charges.

Conclusions

Inpatients with IBD have higher odds of associated thromboembolic disorders compared to patients without IBD. Furthermore, inpatients with IBD and thromboembolic events have significantly higher mortality, morbidity, colectomy rates and resource utilization. For these reasons, increased awareness and specialized strategies for the prevention and management of thromboembolic events should be considered in inpatients with IBD.
Literature
1.
go back to reference Bargen JA, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Archives of internal medicine. 1936;58:17–31.CrossRef Bargen JA, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Archives of internal medicine. 1936;58:17–31.CrossRef
3.
go back to reference Hatoum OA, Spinelli KS, Abu-Hajir M et al. Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol. 2005;39:27–31.PubMed Hatoum OA, Spinelli KS, Abu-Hajir M et al. Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol. 2005;39:27–31.PubMed
4.
go back to reference Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thrombosis and haemostasis. 2001;85:430–434.CrossRefPubMed Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thrombosis and haemostasis. 2001;85:430–434.CrossRefPubMed
5.
go back to reference Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. The American journal of gastroenterology. 2008;103:2272–2280.CrossRefPubMed Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. The American journal of gastroenterology. 2008;103:2272–2280.CrossRefPubMed
6.
go back to reference Kappelman MD, Horvath-Puho E, Sandler RS et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937–943.CrossRefPubMed Kappelman MD, Horvath-Puho E, Sandler RS et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937–943.CrossRefPubMed
7.
go back to reference Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663.CrossRefPubMed Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663.CrossRefPubMed
8.
go back to reference Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Digestive diseases and sciences. 1989;34:1841–1854.CrossRefPubMed Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Digestive diseases and sciences. 1989;34:1841–1854.CrossRefPubMed
9.
go back to reference Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. The American journal of gastroenterology. 2004;99:97–101.CrossRefPubMed Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. The American journal of gastroenterology. 2004;99:97–101.CrossRefPubMed
10.
go back to reference Sarlos P, Szemes K, Hegyi P et al. Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis. Journal of Crohn’s & colitis. 2018;12:489–498.CrossRef Sarlos P, Szemes K, Hegyi P et al. Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis. Journal of Crohn’s & colitis. 2018;12:489–498.CrossRef
11.
go back to reference Andrade AR, Barros LL, Azevedo MFC et al. Risk of thrombosis and mortality in inflammatory bowel disease. Clinical and translational gastroenterology. 2018;9:142–142.CrossRefPubMedPubMedCentral Andrade AR, Barros LL, Azevedo MFC et al. Risk of thrombosis and mortality in inflammatory bowel disease. Clinical and translational gastroenterology. 2018;9:142–142.CrossRefPubMedPubMedCentral
12.
go back to reference Desai RJ, Gagne JJ, Lii J, Liu J, Friedman S, Kim SC. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study. Cmaj. 2017;189:E1438-e1447.CrossRefPubMedPubMedCentral Desai RJ, Gagne JJ, Lii J, Liu J, Friedman S, Kim SC. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study. Cmaj. 2017;189:E1438-e1447.CrossRefPubMedPubMedCentral
13.
go back to reference Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology. 1995;108:1011–1015.CrossRefPubMed Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology. 1995;108:1011–1015.CrossRefPubMed
14.
go back to reference Nguyen GC, Bernstein CN, Bitton A et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835-848.e836.CrossRefPubMed Nguyen GC, Bernstein CN, Bitton A et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835-848.e836.CrossRefPubMed
15.
go back to reference Van Assche G, Dignass A, Bokemeyer B et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1–33.CrossRefPubMed Van Assche G, Dignass A, Bokemeyer B et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1–33.CrossRefPubMed
16.
go back to reference Project HCaU. Introduction to the NIS. City;2016. Project HCaU. Introduction to the NIS. City;2016.
17.
go back to reference Project HCaU. NIS Description of Data Elements. City; Agency for Healthcare Research and Quality;2008. Project HCaU. NIS Description of Data Elements. City; Agency for Healthcare Research and Quality;2008.
18.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology. 1992;45:613–619.CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology. 1992;45:613–619.CrossRefPubMed
19.
go back to reference Cohen JB, Ragni MV, Comer DM, Yabes JG. Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample (NIS) Study. Blood. 2017;130:3372–3372. Cohen JB, Ragni MV, Comer DM, Yabes JG. Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample (NIS) Study. Blood. 2017;130:3372–3372.
20.
go back to reference Yuhara H, Steinmaus C, Corley D et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. 2013;37:953–962. Yuhara H, Steinmaus C, Corley D et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. 2013;37:953–962.
21.
go back to reference Tsai M-S, Lin C-L, Chen H-P, Lee P-H, Sung F-C, Kao C-H. Long-term risk of mesenteric ischemia in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. The American Journal of Surgery. 2015;210:80–86.CrossRefPubMed Tsai M-S, Lin C-L, Chen H-P, Lee P-H, Sung F-C, Kao C-H. Long-term risk of mesenteric ischemia in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. The American Journal of Surgery. 2015;210:80–86.CrossRefPubMed
22.
go back to reference Moores K, Gilchrist B, Carnahan R, Abrams T. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiology and drug safety. 2012;21:194–202.CrossRefPubMed Moores K, Gilchrist B, Carnahan R, Abrams T. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiology and drug safety. 2012;21:194–202.CrossRefPubMed
Metadata
Title
Thromboembolic Events in Hospitalized Patients with Inflammatory Bowel Disease
Authors
Alfred D. Nelson
Daniela Fluxá
Freddy Caldera
Francis A. Farraye
Jana G. Hashash
Paul T. Kröner
Publication date
07-04-2023
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2023
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-07920-6

Other articles of this Issue 6/2023

Digestive Diseases and Sciences 6/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.